Am Fam Physician. 2023;108(4):online
Author disclosure: No relevant financial relationships.
Details for This Review
Study Population: Approximately 90,000 patients with an average age of 50 to 75 years who had hypertension and multiple comorbidities, including type 2 diabetes mellitus; participants had a resting blood pressure of greater than 140 mm Hg systolic or greater than 90 mm Hg diastolic, measured using a standard method on at least two occasions
Efficacy End Points: Total mortality, total morbidity (e.g., serious adverse events, cardiovascular events, stroke, coronary heart disease, congestive heart failure)
| Benefits |
|---|
| Thiazides vs. beta blockers |
| 1 in 45: reduced risk of treatment withdrawal due to adverse effects |
Thiazides vs. calcium channel blockers |
| 1 in 100: reduced risk of cardiovascular events |
| 1 in 84: reduced risk of heart failure |
| 1 in 71: reduced risk of treatment withdrawal due to adverse effects |
Thiazides vs. angiotensin-converting enzyme inhibitors |
| 1 in 167: reduced risk of stroke |
| 1 in 100: reduced risk of treatment withdrawal due to adverse effects |
Thiazides vs. alpha blockers |
| 1 in 33: reduced risk of total cardiovascular events |
| 1 in 39: reduced risk of heart failure |
| 1 in 250: reduced risk of treatment withdrawal due to adverse effects |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
